Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://link.springer.com/doi/10.1007/s00702-008-0177-6 below:

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

• Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006a) CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187

  Article  PubMed  Google Scholar 

• Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, Rüther E, Kornhuber J, Otto M, Wiltfang J (2006b) CSF diagnosis of Alzheimer’s disease and dementias with Lewy bodies. J Neural Transm 113:1771–1778

  Article  PubMed  CAS  Google Scholar 

• Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Ruther E, Kornhuber J, Wiltfang J (2007a) Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol Psy 12:671–680

  Article  CAS  Google Scholar 

• Bibl M, Mollenhauer B, Wolf S, Esselmann H, Lewczuk P, Kornhuber J, Wiltfang J (2007b) Reduced CSF carboxyterminally truncated Aβ petides in frontotemporal lobe degenerations. J Neural Transm 114:621–628

  Article  PubMed  CAS  Google Scholar 

• Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Rüther E, Kornhuber J, Wiltfang J (2004) Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer’s disease (AD) patients and non-demented controls depend on sample pre-treatment: Indication of carrier- mediated epitope masking of Aβ peptides. Electrophoresis 25:2912–2918

  Article  PubMed  CAS  Google Scholar 

• Bibl M, Mollenhauer B, Esselmann H, Schneider M, Lewczuk P, Welge V, Gross M, Falkai P, Kornhuber J, Wiltfang J (2008a) Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cogn Disord 25:256–265

  Article  PubMed  Google Scholar 

• Bibl M, Lewczuk P, Esselmann H, Mollenhauer B, Klafki HW, Welge V, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J (2008b) CSF amyloid-β 1-38 and 1-42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin Appl 2:1548–1556

  Article  CAS  Google Scholar 

• Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx. 1:213–225

  Article  PubMed  Google Scholar 

• De Jong D, Jansen RWMM, Kremer BPH, Verbeek MM (2006) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61:755–758

  PubMed  Google Scholar 

• Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752

  Article  PubMed  CAS  Google Scholar 

• Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890

  Article  PubMed  CAS  Google Scholar 

• Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer’s disease—a comparative study. Arch Gen Psychiatry 61:95–102

  Article  PubMed  CAS  Google Scholar 

• Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD-patients using ß-amyloid (1-42) and tau levels in CSF. Neurology 52:1555–1562

  PubMed  CAS  Google Scholar 

• Ishikawa M (2004) Guideline committee for idiopathic normal pressure hydrocephalus, Japanese society of normal pressure hydrocephalus. Neurol Med Chir 44:222–223

  Article  Google Scholar 

• Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mitsushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol 44:17–26

  Article  PubMed  CAS  Google Scholar 

• Lee VMY, Balin BJ, Otvos L, Trojanowski JQ (1991) A68. A major subunit of paired helical filaments and derivatized forms of normal tau. Science 251:675–678

  Article  PubMed  CAS  Google Scholar 

• Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides. Clin Chem 52:332–334

  Article  PubMed  CAS  Google Scholar 

• Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta 42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 25:273–281

  Article  PubMed  CAS  Google Scholar 

• Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Rüther E, Kornhuber J, Wiltfang J (2003) The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun Mass Spectrom 17:1291–1296

  Article  PubMed  CAS  Google Scholar 

• Litvan I (1997) Progressive supranuclear palsy and corticobasal degeneration. Baillieres Clin Neurol 6:167–185

  PubMed  CAS  Google Scholar 

• Maddalena A, Papassotiropoulos A, Mueller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C (2003) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. Arch Neurol 60:1202–1206

  Article  PubMed  Google Scholar 

• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944

  PubMed  CAS  Google Scholar 

• McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124

  PubMed  CAS  Google Scholar 

• Mehta PD, Pirttila T (2005) Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer’s disease. Neurodegener Dis 2:242–245

  Article  PubMed  CAS  Google Scholar 

• Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P, Schenk D (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 38:643–648

  Article  PubMed  CAS  Google Scholar 

• Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedmann M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobardegeneration. A consensus on clinical diagnostic criteria. Neurology 51:1546–1554

  PubMed  CAS  Google Scholar 

• Oslin D, Aktinsson RM, Smith DM, Hendrie H (1998) Alcohol related dementia: proposed clinical criteria. Int J Ger Psychiatry 13:203–212

  Article  CAS  Google Scholar 

• Roman GC, Tatemichi TK, Erkinjutti T, Cummings JL, Masedeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 43:243–245

  Google Scholar 

• Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD (2005) Amyloid β 38, 40 and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 58:139–142

  Article  PubMed  CAS  Google Scholar 

• Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamuro T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, Mizushima K, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Hirai S (1998) Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci 158:134–140

  Article  PubMed  CAS  Google Scholar 

• Shoji M, Matsubara E, Kanai M, Ikeda M, Harigaya Y, Okamoto K, Hirai S (2000) Taps to Alzheimer’s patients: a continuous Japanese study of cerebrospinal fluid biomarkers. Ann Neurol 48:402

  Article  PubMed  CAS  Google Scholar 

• Shoji M, Kanai M (2001) Cerebrospinal fluid Aβ40 and Aβ42: natural course and clinical usefulness. J Alzheimers Dis 25:273–281

  Google Scholar 

• Shoji M, Kanai M, Matsubara E, Tomidokoro Y, Shizuka M, Ikeda Y, Ikeda M, Harigaya Y, Okamoto K, Hirai S (2001) The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently. Neurobiol Aging 22:209–215

  Article  PubMed  CAS  Google Scholar 

• Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49–52

  Article  PubMed  CAS  Google Scholar 

• Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212–216

  Article  PubMed  CAS  Google Scholar 

• WHO: World Health Organisation (1998) Human transmissible spongiform encephalopathy. Wkly Epidemiol Rec 73:361–365

• Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, Frölich L, Schröder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P (2007) Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-tau in patients with low- and high-CSF Aβ40 load. J Neurochem 101:1053–1059

  Article  PubMed  CAS  Google Scholar 

• Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Anneart W, De Strooper B, Saftig P (2001) Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cells. J Biol Chem 276:42645–42657

  Article  PubMed  CAS  Google Scholar 

• Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Rüther E, Kornhuber J (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and patients with chronic neuroinflammation. J Neurochem. 81:481–496

  Article  PubMed  CAS  Google Scholar 

• World Medical Organisation (1996) Declaration of Helsinki. Br Med J 313:1448–1449

  Google Scholar 

Download references

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.4